Filipe A Moura, MD, PhD
he/him/his
Assistant ProfessorCards
About
Research
Publications
2025
Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial.
Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Kang YM, Murphy SA, Zhang S, Lu MT, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS. Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial. Am Heart J 2025 PMID: 40081744, DOI: 10.1016/j.ahj.2025.02.022.Peer-Reviewed Original ResearchDesign and Rationale of the CORE -TIMI 72a and CORE2 -TIMI 72b Trials of Olezarsen in Patients with Severe Hypertriglyceridemia.
Marston NA, Bergmark BA, Alexander VJ, Karwatowska-Prokopczuk E, Kang YM, Moura FA, Prohaska TA, Zimerman A, Zhang S, Murphy SA, Tsimikas S, Giugliano RP, Sabatine MS. Design and Rationale of the CORE -TIMI 72a and CORE2 -TIMI 72b Trials of Olezarsen in Patients with Severe Hypertriglyceridemia. Am Heart J 2025 PMID: 40064331, DOI: 10.1016/j.ahj.2025.03.003.Peer-Reviewed Original ResearchIdentification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Loesch D, Garg M, Matelska D, Vitsios D, Jiang X, Ritchie S, Sun B, Runz H, Whelan C, Holman R, Mentz R, Moura F, Wiviott S, Sabatine M, Udler M, Gause-Nilsson I, Petrovski S, Oscarsson J, Nag A, Paul D, Inouye M. Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities. Nature Communications 2025, 16: 2124. PMID: 40032831, PMCID: PMC11876343, DOI: 10.1038/s41467-025-56695-z.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCardiovascular DiseasesComorbidityDiabetes Mellitus, Type 2Extracellular Matrix ProteinsFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansInsulin-Like Growth Factor Binding Protein 2MaleMiddle AgedMultifactorial InheritanceProteomicsRisk FactorsUnited KingdomConceptsPolygenic scoresNon-coding variantsEtiology of type 2 diabetesMolecular dataVariant effectsPathway enrichmentPlasma proteomic markersPotential therapeutic targetType 2 diabetesProteinDisease biologyPolygenic riskUK BiobankProteomic markersTherapeutic targetPathwayCirculating proteinsGenomeRisk of type 2 diabetesCardiometabolic scoreBiologyInteractive portalVariantsEnrichmentDiabetes comorbiditiesSkeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes
do A H Souza A, Troschel A, Marquardt J, Hadžić I, Foldyna B, Moura F, Hainer J, Divakaran S, Blankstein R, Dorbala S, Di Carli M, Aerts H, Lu M, Fintelmann F, Taqueti V. Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes. European Heart Journal 2025, 46: 1112-1123. PMID: 39827905, DOI: 10.1093/eurheartj/ehae827.Peer-Reviewed Original ResearchCoronary microvascular dysfunctionBody mass indexCoronary flow reserveIntermuscular adipose tissueSubcutaneous adipose tissueHeart failureFat infiltrationMarker of coronary microvascular dysfunctionPreserved left ventricular ejection fractionCardiovascular outcomesAssociated with coronary microvascular dysfunctionHigher IMATIncreased IMATPresence of coronary microvascular dysfunctionSkeletal muscleFlow reserveIncreased risk of MACEMyocardial infarctionStress positron emission tomographyAssociated with increased MACERisk of heart failureLow coronary flow reserveThoracic vertebra levelVentricular ejection fractionIntermuscular adipose tissue areaA Bayesian Interpretation of CABANA and Other Randomized Controlled Trials for Catheter Ablation in Patients With Atrial Fibrillation
Nogueira A, Felix N, Kalil F, Tramujas L, Godoi A, Miyawaki I, Bellavia A, Moura F, Cardoso R, d'Avila A, Fernandes G. A Bayesian Interpretation of CABANA and Other Randomized Controlled Trials for Catheter Ablation in Patients With Atrial Fibrillation. Journal Of Cardiovascular Electrophysiology 2025, 36: 617-624. PMID: 39834105, DOI: 10.1111/jce.16552.Peer-Reviewed Original ResearchConceptsBayesian analysisTreatment effect distributionAdverse cardiovascular outcomesAll-cause mortalityCardiovascular outcomesRandomized controlled trialsFrequentist estimatorsCatheter ablationMedical therapyAtrial fibrillationBayesian interpretationImpact of catheter ablationControlled trialsAnalysis of randomized controlled trialsProbability distributionAtrial fibrillation patientsReduce adverse cardiovascular outcomesImpact of ablationEffective distributionRandom-effects modelBayes' theoremTrial-level dataProbabilistic understandingSurvival outcomesFibrillation patientsChapter 62 Patient perspectives
Campedelli L, Moura F. Chapter 62 Patient perspectives. 2025, 317-320. DOI: 10.1016/b978-0-323-91790-2.00026-5.Peer-Reviewed Original Research
2024
Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers
Moura F, Kamanu F, Wiviott S, Giugliano R, Udler M, Florez J, Ellinor P, Sabatine M, Ruff C, Marston N. Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers. Diabetes Obesity And Metabolism 2024, 27: 1287-1295. PMID: 39696834, DOI: 10.1111/dom.16123.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLDiabetes Mellitus, Type 2FemaleGenetic Predisposition to DiseaseGlycated HemoglobinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedMultifactorial InheritancePCSK9 InhibitorsPolymorphism, Single NucleotideProprotein Convertase 9Risk FactorsConceptsT2D polygenic scoreBody mass indexProprotein convertase subtilisin/kexin type 9Incident diabetesPolygenic scoresGenetic riskIncident T2DHazard ratioStable atherosclerotic cardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitionYears of median follow-upFurther Cardiovascular Outcomes ResearchRisk factorsMean body mass indexCases of incident diabetesMedian follow-upLower body mass indexPredictor of incident diabetesEffects of evolocumabGenetic risk categoriesLDL cholesterol levelsT2D genetic riskDiabetes risk factorsType 2 diabetes genetic riskAtherosclerotic cardiovascular diseaseDiacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F, Davanzo G, de Brito Monteiro L, Muraro S, de Souza G, Morari J, Galdino F, Brunetti N, Reis-de-Oliveira G, Carregari V, Nadruz W, Martins-de-Souza D, Farias A, Velloso L, Proenca-Modena J, Mori M, Loh W, Bhatt D, Yellon D, Davidson S, De Oliveira P, Moraes-Vieira P, Sposito A. Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study. Frontiers In Pharmacology 2024, 15: 1402032. PMID: 39434905, PMCID: PMC11491754, DOI: 10.3389/fphar.2024.1402032.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsSARS-CoV-2 infectionSARS-CoV-2Viral replicationInflammatory responseInflammasome activationMarkers of inflammasome activationPlacebo-controlled studySuppress viral replicationBlood mononuclear cellsInfection in vitroPrimary metabolitesCOVID-19 patientsDouble-blindPrimary endpointHealthy volunteersSevere acute respiratory syndrome coronavirus 2Plasma markersAcute respiratory syndrome coronavirus 2Mononuclear cellsClinical trialsRespiratory syndrome coronavirus 2Day 2Syndrome coronavirus 2Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
Moura F, Bellavia A, Berg D, Melloni G, Feinberg M, Leiter L, Bohula E, Morrow D, Scirica B, Wiviott S, Sabatine M. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obesity And Metabolism 2024, 26: 4441-4449. PMID: 39056220, PMCID: PMC11410501, DOI: 10.1111/dom.15798.Peer-Reviewed Original ResearchNew-onset diabetesRisk of new-onset diabetesClinical risk modelWeight loss therapyRisk groupsWeight loss pharmacotherapyMultivariate Cox regressionStable cardiovascular patientsTherapeutic decision makingAbsolute risk reductionHigh-risk groupType 2 diabetesIndependent predictorsValidation cohortFollow-upPersonalized patient careCox regressionHazard ratioPrimary outcomeRisk modelHigh riskInterquartile rangePatientsDiabetesCardiovascular patients1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58
MI KANG Y, MELLONI G, CAHN A, RAZ I, MOURA F, BHATT D, INZUCCHI S, LEITER L, MCGUIRE D, WILDING J, GAUSE-NILSSON I, OSCARSSON J, MARSTON N, RUFF C, SABATINE M, WIVIOTT S. 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58. Diabetes 2024, 73 DOI: 10.2337/db24-1896-lb.Peer-Reviewed Original ResearchDuke Clinical Research InstituteC-pepClinical Research InstituteDKA eventsC-peptideLower fasting C-peptideMedian follow-upRandomized to dapagliflozinFasting C-peptideDuration of T2DC-peptide testingRisk of DKACV outcome trialsAmerican College of CardiologyAbsolute risk differenceRate of DKAImpaired insulin secretionType 2 diabetesPlacebo armClinical featuresPopulation Health Research InstituteCSL BehringDiabetic ketoacidosisFerring PharmaceuticalsOutcome trials